Results 291 to 300 of about 723,696 (347)

A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours.

European Journal of Cancer, 2013
I. Macpherson, S. Poondru, G. Simon, R. Gedrich, K. Brock, C. Hopkins, K. Stewart, A. Stephens, T. Evans   +8 more
semanticscholar   +1 more source

[3H]ICS 205-930 labels 5-HT3 recognition sites in membranes of cat and rabbit vagus nerve and superior cervical ganglion

Naunyn-Schmiedeberg's Archives of Pharmacology, 1989
Daniel Hoyer, Christian Waeber, José M Palacios   +2 more
exaly  

Assessment of a process to degrade metal working fluids using Pseudomonas stutzeri CECT 930 and indigenous microbial consortia.

Chemosphere, 2012
F. Moscoso, F. Deive, P. Villar, R. Pena, L. Herrero, M. Longo, M. Sanromán   +6 more
semanticscholar   +1 more source

930. Nimrod

Vacuum, 1964
openaire   +1 more source

Similar effects of diazepam and the 5-HT3 receptor antagonist ICS 205-930 on place aversion conditioning

European Journal of Pharmacology, 1988
Mariusz Papp
exaly  

Specific decreases in ethanol- but not water-reinforced responding produced by the 5-HT3 antagonist ICS 205-930

Alcohol, 1993
Clyde W Hodge
exaly  

The abilities of 5-HT3 receptor antagonist ICS 205-930 to inhibit alcohol preference and withdrawal seizures in rats

Alcohol, 1993
Wanda Dyr, Paweł Krząścik
exaly  

(930) Westphalia

2003
openaire   +1 more source

Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure.

Journal of the American Podiatric Medical Association (Print), 2010
A. Landsman, A. Robbins, P. Angelini, Catherine C Wu, Jeremy J. Cook, M. Oster, Eric S Bornstein   +6 more
semanticscholar   +1 more source

MWC 930 -- a new luminous blue variable candidate

Monthly Notices of the Royal Astronomical Society, 2005
Anatoly S Miroshnichenko, Konstantin N Grankin   +1 more
exaly